Latest Breaking News On - Campbellp patisiran - Page 1 : comparemela.com

Announced on October 9, the decision to issue a CRL is based on the FDA's belief the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established.

United statesKunzmannk patisiranCampbellp patisiranAhmad masriChristopher oconnorYvonne greenstreetAlnylam pharmaceuticalsInvestor relations alnylam pharmaceuticals incOregon healthRenal drugs advisory committeeVascular instituteHypertrophic cardiomyopathy centerDrug administrationSciences universityComplete response letterChief executive officer